Last reviewed · How we verify

NCT05368480

Evaluating the Impact of Senior Companion Programs

Status unknown NA Last updated 1 June 2022
What this trial tests

NA trial testing Senior Companion Program in Aging in 1,040 participants. Status unknown.

Timeline
2 May 2022
Primary endpoint
1 December 2025
1 December 2025

Quick facts

Lead sponsorWilliam Evans
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment1,040
Start date2 May 2022
Primary completion1 December 2025
Estimated completion1 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

William Evans

Who can join

21 and older, any sex, with Aging or Disabilities Multiple. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Senior Companion Programs (SCP) facilitate partnerships between community volunteers and local homebound seniors. Seniors served by the SCP will be provided with a companion who will conduct weekly visits with them, help with meal preparation or deliveries, provide transportation, assist with simple housekeeping, and socialize with the client amongst other tasks. These services are directed towards helping the senior client continue living independently in their own home instead of moving into an assisted living or nursing home. The SCP model is being evaluated to determine the impact of the services on the client's overall well-being and independent living status.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aging

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05368480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing